BioCatalystWatch
ORICWorkspace / ORIC / OverviewCompany library
Oric Pharmaceuticals, Inc. logo

Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc. (ORIC)

Website

Price
Market cap
Next catalystExpected 1H 2027Enozertinib — Redwood-1 planned Phase 3 monotherapy · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

EED × PRC2

Enozertinib

EGFR × HER2

PreINDP1P2FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Enozertinib

EGFR × HER2

PreINDP1P2FilingApproved
Upcoming / outlook

EED × PRC2

Other pipelines

Enozertinib

EGFR × HER2

PreINDP1P2P3FilingApproved

EED × PRC2

PreINDP1P2P3FilingApproved

EED × PRC2

EED × PRC2

PreINDP1P2P3FilingApproved

EED × PRC2

PreINDP1P2P3FilingApproved
ORIC-613

PLK4

Partner / License out

CIP2A mRNA

History / paused

Glucocorticoid receptor (GR)

PreINDP1P2P3FilingApproved

Glucocorticoid receptor (GR)

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ORIC PR & News

ORIC SEC archive